Introduction: Challenging the Paracetamol-Atopy Hypothesis
For over two decades, a persistent debate has permeated pediatric medicine regarding the safety of early-life paracetamol (acetaminophen) exposure. Numerous observational studies, most notably the International Study of Asthma and Allergies in Childhood (ISAAC), have reported associations between paracetamol use in infancy and an increased prevalence of asthma, wheezing, and eczema. These findings led to the biological hypothesis that paracetamol might deplete systemic glutathione, inducing oxidative stress and shifting the immune response toward a Th2-mediated allergic profile.
However, observational data are inherently susceptible to confounding by indication—where the underlying infection or fever that necessitates the antipyretic, rather than the drug itself, is the true driver of subsequent atopic disease. To address this critical evidence gap, the PIPPA Tamariki trial was designed as a robust, randomized controlled trial (RCT) to compare paracetamol with ibuprofen for fever or pain in the first year of life, focusing on the development of eczema and bronchiolitis.
